Fundraising Fox

Belenosbio

New York, US · Founded 2024 · 1 known investors

Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU. Its pipeline includes BEL512 (targeting TSLP and IL-13) and BEL536 (targeting OX40L and IL-13), both aimed at modulating type 2 inflammation.

Founders & leadership

Belenosbio was founded in 2024 by Donnie McGrath, Megan Dow, Tania Dimitrova, and Glenn Rosen.

DMDonnie McGrath
Donnie McGrathCEO & Co-Founder
MDMegan Dow
Megan DowCOO & Co-Founder
TDTania Dimitrova
Tania DimitrovaCFO & Co-Founder
GRGlenn Rosen
Glenn RosenChief Translational Officer & Co-Founder
SD
StJohn Donnie McGrathExecutive

Board

BC
Bo ChenBoard director
CGCarl Gordon
Carl GordoninBoard directorManaging Partner at OrbiMed
DWDavid Wang
David WanginBoard directorPartner at OrbiMed

Investors · 1

Reported raises · per SEC filings

Form D private placements

$48M disclosed across 1 round · 2024

$48MraisedJul 2024 · 2 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Bo ChenDirector
  • Carl GordonDirector
  • Tania DimitrovaExecutive Officer
  • David WangDirector
  • Megan DowExecutive Officer
  • StJohn Donnie McGrathExecutive Officer, Director
Offering amount
$55M
Amount sold
$48M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Belenosbio do?
Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU. Its pipeline includes BEL512 (targeting TSLP and IL-13) and BEL536 (targeting OX40L and IL-13), both aimed at modulating type 2 inflammation.
Who founded Belenosbio?
Belenosbio was founded by Donnie McGrath, Megan Dow, Tania Dimitrova, Glenn Rosen in 2024.
Who are Belenosbio's investors?
Belenosbio's investors include OrbiMed.
How much funding has Belenosbio raised?
Belenosbio has disclosed $48M raised across 1 round.
Where is Belenosbio headquartered?
Belenosbio is headquartered in New York, US.